Awardee OrganizationUNIVERSITY OF CALIFORNIA, SAN FRANCISCO
Description
Abstract Text
Basic pharmacological research aimed at identifying drugs that may correct the cellular
derangements that lead to the debilitating and often fatal lung disease associated with cystic
fibrosis requires a continuing and dependable source of cystic fibrosis and "normal" respiratory
tissues. Cell culture techniques that allow the propagation of respiratory epithelial cells and
formation of differentiated cell culture model systems provide a necessary and powerful tool for
testing candidate drugs. Thus, the primary objective of the Cell Models Core is the collection of CF and non-CF respiratory tract tissues and the preparation of differentiated cultures of the respiratory surface epithelial cells and the tracheobronchial submucosal gland cells. A secondary objective of the Cell Models Core is to identify cell culture conditions that permit full expression of differentiated cellular functions, particularly in cell cultures that have been expanded by serial propagation. A tissue procurement system has been established for obtaining both CF and control nasal and airway tissues. Procured tissue is enzymatically digested, and liberated surface epithelial and submucosal gland acinar cells are established as cell cultures. The surface epithelial cells are studied as primary cell cultures of highly differentiated cell sheets that mimic the structure and function of the native nasal and airway epithelium. To increase the number of cell sheets available for screening compounds, some cell cultures are also expanded by serial propagation. The initial primary cultures of the tracheobronchial gland cells are expanded and then seeded as secondary cultures for experimental use. The conditions in which the passaged gland cells are grown are manipulated to produce cells expressing either a mucous or serous cell phenotype. Having respiratory epithelial cells derived from both the mucosal surface and the submucosal gland cells
allows investigators to test candidate drugs for action in the various respiratory tract cells most
affected in cystic fibrosis.
National Institute of Diabetes and Digestive and Kidney Diseases
CFDA Code
DUNS Number
094878337
UEI
KMH5K9V7S518
Project Start Date
01-July-2005
Project End Date
30-June-2010
Budget Start Date
01-July-2005
Budget End Date
31-July-2006
Project Funding Information for 2005
Total Funding
$136,230
Direct Costs
$89,921
Indirect Costs
$46,309
Year
Funding IC
FY Total Cost by IC
2005
National Institute of Diabetes and Digestive and Kidney Diseases
$136,230
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1P30DK072517-01 9003
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1P30DK072517-01 9003
Patents
No Patents information available for 1P30DK072517-01 9003
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1P30DK072517-01 9003
Clinical Studies
No Clinical Studies information available for 1P30DK072517-01 9003
News and More
Related News Releases
No news release information available for 1P30DK072517-01 9003
History
No Historical information available for 1P30DK072517-01 9003
Similar Projects
No Similar Projects information available for 1P30DK072517-01 9003